Olaparib: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
<scene name='10/1001156/Overall/1'>Poly [ADP-ribose] polymerase 2 in complex with Olaparib</scene> ([[4tvj]]). | <scene name='10/1001156/Overall/1'>Poly [ADP-ribose] polymerase 2 in complex with Olaparib</scene> ([[4tvj]]). | ||
See also: | |||
*[[Mutations in BRCA1/BARD1 RING-domain heterodimer]] | |||
*[[Mutations in Brca1 BRCT Domains]] | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 09:25, 19 October 2023
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.[1] See also Olaparib. (4tvj). See also: |
| ||||||||||
ReferencesReferences
- ↑ Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123-34. PMID:19553641 doi:10.1056/NEJMoa0900212